Cargando…

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines

BACKGROUND: Although programmed cell death-1/programmed death-ligand 1 (PD-L1) inhibitors show remarkable antitumor activity, a large portion of patients with cancer, even those with high PD-L1-expressing tumors, do not respond to their effects. Most PD-L1 inhibitors contain modified fragment crysta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Ji-Eun, Kim, Seong-Eun, Keam, Bhumsuk, Park, Ha-Ram, Kim, Soyeon, Kim, Miso, Kim, Tae Min, Doh, Junsang, Kim, Dong-Wan, Heo, Dae Seog
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445348/ https://www.ncbi.nlm.nih.gov/pubmed/32830112 http://dx.doi.org/10.1136/jitc-2020-000873

Ejemplares similares

TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment
por: Park, Miso, et al.
Publicado: (2023)

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
por: Kim, Su-Jung, et al.
Publicado: (2019)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression
por: Lv, Tingting, et al.
Publicado: (2022)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
por: Oh, So Yeon, et al.
Publicado: (2021)

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
por: Lejeune, Pascale, et al.
Publicado: (2021)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Xu, Yiqi, et al.
Publicado: (2021)

HLA‐B27 association of autoimmune encephalitis induced by PD‐L1 inhibitor
por: Chang, Hyeyeon, et al.
Publicado: (2020)

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
por: Kortekaas, Kim E, et al.
Publicado: (2021)

Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis
por: Park, Ha-Ram, et al.
Publicado: (2022)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
por: Zhang, Tingting, et al.
Publicado: (2022)

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
por: Rong, Dawei, et al.
Publicado: (2023)

4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39(+) CD8 T cells from primary and metastatic sites of epithelial ovarian cancers
por: Leem, Galam, et al.
Publicado: (2020)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma
por: Church, Candice, et al.
Publicado: (2022)

Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis
por: Ho, Tuyen Thuy Bich, et al.
Publicado: (2020)

PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma
por: Ock, Chan-Young, et al.
Publicado: (2016)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
por: Liu, Jiaxin, et al.
Publicado: (2022)

Local IFNα enhances the anti-tumoral efficacy of systemic anti-PD1 to prevent tumor relapse
por: Guerin, Marion v, et al.
Publicado: (2020)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
por: Mehnert, Janice M., et al.
Publicado: (2019)

A Novel Anti-PD-L1 Antibody Exhibits Antitumor Effects on Multiple Myeloma in Murine Models via Antibody-Dependent Cellular Cytotoxicity
por: Ahn, Jae-Hee, et al.
Publicado: (2021)

Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation
por: Zhu, Lin, et al.
Publicado: (2022)

DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma
por: Fitzgerald, Allison A, et al.
Publicado: (2021)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment
por: Pizzolla, Angela, et al.
Publicado: (2022)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
por: Bellastella, Giuseppe, et al.
Publicado: (2021)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody
por: Katoh, Yuki, et al.
Publicado: (2022)

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1(low) and immune desert-like mouse tumors
por: Ishikura, Nobuyuki, et al.
Publicado: (2022)

A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy
por: Sánchez-Alonso, Santiago, et al.
Publicado: (2020)

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2022)

Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation
por: Wu, Bogang, et al.
Publicado: (2020)

Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer
por: Li, Gaopeng, et al.
Publicado: (2021)

Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells
por: Chen, Heyu, et al.
Publicado: (2020)

Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1
por: Makowska, Anna, et al.
Publicado: (2020)

ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers
por: Yu, Zheng-Zheng, et al.
Publicado: (2023)

Product review: avelumab, an anti-PD-L1 antibody
por: Collins, Julie M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vord7apbadjndo7lhrcf0umv4v